Central dopamine turnover in schizophrenic syndromes.
D000342:Affective Symptoms / Q000134:cerebrospinal fluid / Q000188:drug therapy / Q000378:metabolism; D002746:Chlorpromazine / Q000627:therapeutic use; D004298:Dopamine / Q000378:metabolism*; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008297:Male; D011339:Probenecid / Q000008:administration & dosage / Q000134:cerebrospinal fluid; D012559:Schizophrenia / Q000134:cerebrospinal fluid / Q000188:drug therapy / Q000378:metabolism*; D013577:Syndrome; D013997:Time Factors; D014268:Trifluoperazine / Q000627:therapeutic use
D014268:Trifluoperazine; D006897:Hydroxyindoleacetic Acid; D011339:Probenecid; D002746:Chlorpromazine; D004298:Dopamine; D006719:Homovanillic Acid